Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Mingjian Ma

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5115595210. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2023: 5 papers · 2024: 9 papers · 2025: 2 papers · 2026: 3 papers

Papers 19

  1. Positive Feedback Loop of Histone Lactylation-Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance. Co-author DOI 10.1002/advs.202510483↗
  2. Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.77048↗
  3. CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70776↗
  4. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  5. Auranofin facilitates gemcitabine sensitivity by regulating TXNRD1-related ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2025.218058↗
  6. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202406714↗
  7. Platelet-Derived Growth Factor C Facilitates Malignant Behavior of Pancreatic Ductal Adenocarcinoma by Regulating SREBP1 Mediated Lipid Metabolism. Co-author DOI 10.1002/advs.202407069↗
  8. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03648-y↗
  9. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03786-3↗
  10. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167346↗
  11. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Co-author DOI 10.1016/j.canlet.2024.216640↗
  12. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  13. Turning to immunosuppressive tumors: Deciphering the immunosenescence-related microenvironment and prognostic characteristics in pancreatic cancer, in which GL… Co-author DOI 10.1016/j.heliyon.2024.e36684↗
  14. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Co-author DOI 10.1038/s41388-024-03092-3↗
  15. Laparoscopic pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction for pancreatic cancer: A single-center experience. Co-author DOI 10.1016/j.hbpd.2023.01.004↗
  16. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Co-author DOI 10.1136/jitc-2023-006698↗
  17. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  18. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30020126↗
  19. Adipocytes promote pancreatic cancer migration and invasion through fatty acid metabolic reprogramming. Co-author DOI 10.3892/or.2023.8578↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ying‐Qin Zhu · 9 shared papers, 2024–2026 · strength 2.10
  2. Zhide Liu · 8 shared papers, 2024–2026 · strength 1.81
  3. Xianjun Yu · 9 shared papers, 2023–2025 · strength 1.73
  4. Xiao-Yu Yin · 7 shared papers, 2024–2026 · strength 1.60
  5. Yusheng Chen · 8 shared papers, 2023–2025 · strength 1.57
  6. Xuan Lin · 8 shared papers, 2023–2025 · strength 1.50
  7. Xuan Zou · 7 shared papers, 2023–2025 · strength 1.31
  8. Yesiboli Tasiheng · 7 shared papers, 2023–2024 · strength 1.25
  9. Zhengjie Dai · 7 shared papers, 2023–2024 · strength 1.25
  10. He Cheng · 6 shared papers, 2023–2025 · strength 1.19
  11. De-Liang Fang · 4 shared papers, 2024–2026 · strength 1.05
  12. Siyuan Lu · 4 shared papers, 2024–2026 · strength 1.05
  13. Xi‐Tai Huang · 5 shared papers, 2024–2026 · strength 1.04
  14. Chen Liu · 5 shared papers, 2023–2025 · strength 0.98
  15. Yin-Hao Shi · 5 shared papers, 2024 · strength 0.97
  16. Xu Wang · 5 shared papers, 2023–2025 · strength 0.91
  17. Yu Yan · 4 shared papers, 2023–2025 · strength 0.76
  18. Jie‐Qin Wang · 4 shared papers, 2024 · strength 0.75
  19. Chen Liu · 3 shared papers, 2023–2024 · strength 0.55
  20. He Cheng · 2 shared papers, 2024 · strength 0.39
  21. Xiao‐Yu Yin · 1 shared paper, 2026 · strength 0.28
  22. Xiao Yu Yin · 1 shared paper, 2024 · strength 0.22
  23. Zhiwei Cai · 1 shared paper, 2023 · strength 0.20
  24. Chongyi Jiang · 1 shared paper, 2023 · strength 0.20
  25. Chen Liu · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.